Q-omics provides the consensus-scored TKTL1 profile across patient tissues and cancer cell-line models. TKTL1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TKTL1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TKTL1 RNA expression shows 14,403 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, COAD, and KIRP as cancer lineages where TKTL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TKTL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TKTL1 survival associations across molecular data types. TKTL1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TKTL1 RNA expression–survival associations across cancer types. High TKTL1 expression shows unfavorable associations in UVM, ACC, SCLC and KICH, but favorable associations in LUAD and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TKTL1 RNA expression.
This table summarizes TKTL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TKTL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TKTL1 shows lower tumor expression in COAD, BRCA, THCA and LUAD and higher tumor expression in STAD and ESCA. The COAD box plot shows higher TKTL1 RNA expression in normal versus tumor tissue (log2 FC = −0.078, t-test p = .002).
This table shows molecular features associated with TKTL1 in patient tissues and cancer cell lines. In patient samples, TKTL1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TKTL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
